Moreover, a recent study reports that, in a cohort of 1,213 hospitalized patients with COVID-19 and pre-existing T2D, metformin use is significantly associated with reduced heart failure and decreased circulating inflammatory markers, such as CRP, IL-6, IL-2, and TNF-α. Here, IL2 is linked to heart failure.